A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease which continues to carry an unacceptably high mortality and morbidity. The nitric oxide (NO) pathway has been implicated in the pathophysiology and progression of the disease. Its extremely short half-life and systemic effect...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Cardiovasc Transl Res
Autors principals: Mohamed, Nura A., Ahmetaj-Shala, Blerina, Duluc, Lucie, Mackenzie, Louise S., Kirkby, Nicholas S., Reed, Daniel M., Lickiss, Paul D., Davies, Robert P., Freeman, Gemma R., Wojciak-Stothard, Beata, Chester, Adrian H., El-Sherbiny, Ibrahim M., Mitchell, Jane A., Yacoub, Magdi H.
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2016
Matèries:
Correspondence
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4830862/
https://ncbi.nlm.nih.gov/pubmed/26960567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12265-016-9684-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars